ArticleJAAD international2021
Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.
Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches.Annals of medicine · 2026Review
- Post-COVID Hair Loss in the Indian Subcontinent: Clinical Patterns and Association with Disease Severity.Dermatology practical & conceptual · 2025Article
- Relationship Between Anemia and Telogen Effluvium in Post-COVID-19 Survivors.Dermatology practical & conceptual · 2025Article
- The Difference Between SARS-CoV-2 Associated Telogen Effluvium and Telogen Effluvium Due to Other Causes.Dermatology practical & conceptual · 2024Article
- The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection.Archives of dermatological research · 2024Review
- COVID-19-induced hair shedding and related risk factors: A Saudi perspective.Journal of family medicine and primary care · 2023Article
- A Cross-Sectional Study on Post-Coronavirus Disease (COVID-19) Hair Loss at a Tertiary Care Hospital.Dermatology practical & conceptual · 2023Article
- [Review of the post-COVID-19 syndrome associated to acute telogen effluvium].Revista medica del Instituto Mexicano del Seguro Social · 2023Review
- SARS-CoV-2 Infection-A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case-Based Guidance for Clinical Evaluation.Life (Basel, Switzerland) · 2023Review
- COVID-19-Related Neuropathic Pain: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Article
- Short- and mid-term outcomes of multisystem inflammatory syndrome in children: a longitudinal prospective single-center cohort study.Frontiers in pediatrics · 2023Article
- Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia.Annals of medicine · 2022Article
- Telogen effluvium after COVID-19 vaccination among public in Saudi Arabia.Journal of family medicine and primary care · 2022Article
- Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.The Journal of dermatology · 2022Review
- Post SARS-CoV-2 vaccination effluviumEuropean journal of dermatology : EJD · 2022Article
- Characteristics of hair loss after COVID-19: A systematic scoping review.Journal of cosmetic dermatology · 2022Article
- Intermittent chronic telogen effluvium with an unusual dermoscopic finding following COVID-19.Clinical case reports · 2022Article
- Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization.Journal of the American Academy of Dermatology · 2022Article
- Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?Journal of cosmetic dermatology · 2022Observational
- Long COVID: current status in Japan and knowledge about its molecular background.Global health & medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported.
objectiveTo evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease.
methodsPatients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms.
resultsData from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. LIMITATIONS: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities.
conclusionThe severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.